Evaluation of cloned cells, animal model, and ATRA sensitivity of human testicular yolk sac tumor

Zhao, Jiawen; Chen, Congde; Zhang, Haochuan; Shen, Jinhui; Zhang, Hua; Lin, Xiaokun; Qin, Le; Bao, Xiaozhou; Lin, Jie; Lu, Wenqiang; Wang, Xiangdong; Chen, Xiaoming

doi:10.1186/1479-5876-10-46

Cited by 5 publications

(9 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pediatric germ cell tumors account for 60–75% of pediatric testicular tumors, mostly as YSTs. The occurrence of the tumor in the cerebellar hemisphere is extremely rare and few cases have been reported in the literature ( 2 ). Endodermal sinus tumors, also known as YSTs, belong to an inferior class of germ cell tumors (GCTs) with a poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Primary cerebellar endodermal sinus tumor: A case report

et al. 2014

View full text Add to dashboard Cite

Endodermal sinus tumors are rare malignant germ cell tumors that usually originate from the gonads and are rarely observed extragonadally. Pure primary endodermal sinus tumors of the cerebellar hemisphere are extremely rare and patients diagnosed with the disease often have a poor prognosis. The symptoms of YSTs are unspecific and associated with the location of tumors. Intracranial YSTs (such as cerebellar hemispheres) always present with symptoms including headache and poor vision. The present study reports the case of a three-year-old male who presented to The First Affiliated Hospital of Nanchang University (Nanchang, China) with a headache that had persisted for one month, and then worsened for the last 10 days. This was accompanied by vomiting and gait disturbance. An abnormal signal mass was identified in the left cerebellar hemisphere on brain magnetic resonance imaging. The case initially presented as a medulloblastoma and the patient was followed up for six months. The final pathology report revealed an endodermal sinus tumor, also known as a yolk sac tumor. Six months following resection of the left cerebellar tumor, the patient succumbed to recurrence of the disease, due to acute vomiting and severe headache.

show abstract

Section: Introductionmentioning

confidence: 99%

Primary cerebellar endodermal sinus tumor: A case report

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The effects of a new generation drug named NVP-BEZ-235 that inhibits mTOR on proliferation, and apoptosis were reported previously because prior work suggested that NVP-BEZ-235 alone or the combination of NVP-BEZ-235 with another drug effectively slow down cancer cell proliferation [5]. Six human hepatocellular carcinoma cell lines including 97H, 97L, A3, F11, MHCC1 and SMMC7721, which recapitulate features of human liver cancers because these lines [6,7] were chosen to test the drug effects in the cell proliferation.…”

Section: N V P -B E Z -2 3 5 a N D S H B M 1 0 0 9 E F F E C T S O N mentioning

confidence: 85%

“…Six human hepatocellular carcinoma cell lines including 97H, 97L, A3, F11, MHCC-1, SMMC7721, and one gastric cell line, SGC-7901 cells, were purchased from the Cell Bank of Shanghai Institutes for Biological Science (CAS). TYST testicular cancer cell line was established by our group from the primary tissue of a patient [5]. They were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS (Biowest, France) and penicillin (100 U/mL)/streptomycin (100 mg/mL).…”

Section: Cell Culturementioning

confidence: 99%

Effects of phosphoinositide 3-kinase inhibitor SHBM1009 on cancer cells proliferation

Wang

Huang

Shen

et al. 2018

MCT

View full text Add to dashboard Cite

BACKGROUND: Phosphoinositide 3-kinase (PI3K) plays an important role in cellular proliferation and tumor progression. The objective of this study is to evaluate the potential mechanism and therapeutic effects of new PI3K inhibitor SHBM1009 on various cancer cells of digestive system on proliferation. METHODS: Six human hepatocellular carcinoma cell lines including 97H, 97L, A3, F11, MHCC-1, SMMC7721, one gastric cell line SGC-7901 and three primary testicular cancer TYST,TYST1,TYST2 cells were treated by 100ng/ml epidermal growth factor with or without 1uM NVP-BEZ-235 and SHBM1009 in Cell-IQ system in 24-well plates for 48h and up to 72h. The cell bio-behaviors, especially for cell proliferation of total cell number were measured by a real-time cell monitoring system, Cell-IQ continuous cell culturing platform. Images were captured at 30 min intervals. Cell-IQ system uses machine vision technology for monitoring and recording time-lapse data, and the cell functions and morphological parameters were quantified and analyzed. RESULTS: SHBM1009 could prevent EGF-induced cancer cells proliferation. Different patterns of inhibitory effects of SHBM1009 and NVP-BEZ-235, a dual PI3K/mechanistic target of rapamycin inhibitor, on EGF-induced cancer cells proliferation were observed. CONCLUSIONS: PI3K plays a critical role in the development of cancer progress, including proliferation, differentiation and anti-apoptosis. SHBM1009, a new PI3K inhibitor, could be new therapeutic alternatives for cancer treatment.

show abstract

“…Tumor antigens that can be recognized and attacked by host's adaptive immune responses are essential to effective antitumor immunotherapy. GPC3, as a carcinoembryonic antigen, is an ideal target for antitumor immunotherapy, because its expression is up‐regulated in many types of pediatric solid tumors, especially in YSTs 6,18 . Previous studies have shown that vaccination with GPC3 144‐152 peptide induces potent CD8 + T‐cell immunity against various types of cancers in rodents and in clinical trials 8,32 .…”

Section: Discussionmentioning

confidence: 99%

“…It is notable that YST is the commonest GCT in preadolescent testicular tumors, and expresses high levels of GPC3 17 . Unfortunately, treatment of TYST still depends on surgical resection and/or chemotherapy 18 . Currently, there are few studies to explore the potential of GPC3 peptide‐based vaccines for treatment of TYST.…”

Section: Introductionmentioning

confidence: 99%

Administration of a glypican‐3 peptide increases the infiltration and cytotoxicity of CD8⁺ T cells against testicular yolk sac tumor, associated with enhancing the intratumoral cGAS/STING signaling

Zhao,

Qin,

et al. 2023

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

BackgroundGlypican‐3 (GPC3) is highly expressed in testicular yolk sac tumor (TYST). GPC3 has been evaluated as a cancer vaccine for some types of tumors, but little is known on the effects of GPC3 peptide‐based therapy on TYST. Here, we evaluated the antitumor effect of GPC3144‐152 on TYST and its potential mechanisms.MethodsGPC3144‐152‐specific CD8+ T cells were induced by vaccine immunization and examined by ELISPOT. The CD8+ T cells were purified for testing their cytotoxicity in vitro against TYST cells by CCK‐8 and TUNEL assays and in vivo against tumor growth. The influence of GPC3144‐152 loading and/or cGAS silencing on the tumor growth, apoptosis and cGAS/STING signaling was tested by immunohistochemistry, immunofluorescence, flow cytometry, and Western blot.ResultsVaccination with GPC3144‐152 induced tumor‐specific CD8+ T cells that secreted high levels of IFN‐γ and granzyme B, and had potent cytotoxicity against TYST in a dose‐dependent manner. Adoptive transfer of CD8+ T cells and treatment with GPC3144‐152 significantly inhibited the growth of TYST tumors, but less effective for cGAS‐silenced TYST tumors in vivo. Treatment with GPC3144‐152 enhanced the infiltration of CD8+ T cells into the tumor environment and their cytotoxicity against TYST tumors in vivo by up‐regulating granzyme B and IFN‐β expression, but down‐regulating GPC3 expression in the tumors. Co‐culture of CD8+ T cells with TYST in the presence of exogenous GPC3144‐152 enhanced peptide‐specific CD8+ T‐cell cytotoxicity in vitro, accompanied by enhancing cGAS, γH2AX, TBK1, and IRF3 phosphorylation in TYST cells, but less effective in cGAS‐silenced TYST cells.ConclusionsThese data indicated that GPC3 peptide‐specific CD8+ T cells had potent antitumor activity against TYST tumor, particularly for combined treatment with the peptide, which was partially dependent on the intratumoral cGAS/STNG signaling. GPC3 peptide vaccine may be valuable for the combination treatment of TYST.

show abstract

Evaluation of cloned cells, animal model, and ATRA sensitivity of human testicular yolk sac tumor

Cited by 5 publications

References 44 publications

Primary cerebellar endodermal sinus tumor: A case report

Primary cerebellar endodermal sinus tumor: A case report

Effects of phosphoinositide 3-kinase inhibitor SHBM1009 on cancer cells proliferation

Administration of a glypican‐3 peptide increases the infiltration and cytotoxicity of CD8⁺ T cells against testicular yolk sac tumor, associated with enhancing the intratumoral cGAS/STING signaling

Contact Info

Product

Resources

About

Evaluation of cloned cells, animal model, and ATRA sensitivity of human testicular yolk sac tumor

Cited by 5 publications

References 44 publications

Primary cerebellar endodermal sinus tumor: A case report

Primary cerebellar endodermal sinus tumor: A case report

Effects of phosphoinositide 3-kinase inhibitor SHBM1009 on cancer cells proliferation

Administration of a glypican‐3 peptide increases the infiltration and cytotoxicity of CD8+ T cells against testicular yolk sac tumor, associated with enhancing the intratumoral cGAS/STING signaling

Contact Info

Product

Resources

About

Administration of a glypican‐3 peptide increases the infiltration and cytotoxicity of CD8⁺ T cells against testicular yolk sac tumor, associated with enhancing the intratumoral cGAS/STING signaling